Literature DB >> 26742473

Statin Use and the Risk of Kidney Disease With Long-Term Follow-Up (8.4-Year Study).

Tushar Acharya1, Jian Huang2, Steven Tringali3, Christopher R Frei4, Eric M Mortensen5, Ishak A Mansi6.   

Abstract

Few studies have examined long-term effects of statin therapy on kidney diseases. The objective of this study was to determine the association of statin use with incidence of acute and chronic kidney diseases after prolonged follow-up. In this retrospective cohort study, we analyzed data from the San Antonio area military health care system from October 2003 through March 2012. Statin users were propensity score matched to nonusers using 82 baseline characteristics including demographics, co-morbidities, medications, and health care utilization. Study outcomes were acute kidney injury, chronic kidney disease (CKD), and nephritis/nephrosis/renal sclerosis. Of the 43,438 subjects included, we propensity score matched 6,342 statin users with 6,342 nonusers. Statin users had greater odds of acute kidney injury (odds ratio [OR] 1.30, 95% confidence interval [CI] 1.14 to 1.48), CKD (OR 1.36, 95% CI 1.22 to 1.52), and nephritis/nephrosis/renal sclerosis (OR 1.35, 95% CI 1.05 to 1.73). In a subset of patients without co-morbidities, the association of statin use with CKD remained significant (OR 1.53, 95% CI 1.27 to 1.85). In a secondary analysis, adjusting for diseases/conditions that developed during follow-up weakened this association. In conclusion, statin use is associated with increased incidence of acute and chronic kidney disease. These findings are cautionary and suggest that long-term effects of statins in real-life patients may differ from shorter term effects in selected clinical trial populations. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26742473     DOI: 10.1016/j.amjcard.2015.11.031

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  12 in total

1.  Do Statins Increase the Risk of Esophageal Conditions? Findings from Four Propensity Score-Matched Analyses.

Authors:  Ioana Smith; Robert Schmidt; Ethan A Halm; Ishak A Mansi
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

2.  Effects of statins on the kidneys in patients with type 2 diabetes.

Authors:  Ko Hanai; Tetsuya Babazono; Yasuko Uchigata
Journal:  Clin Exp Nephrol       Date:  2016-09-15       Impact factor: 2.801

3.  Long-term effects of various types of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on changes in glomerular filtration rate in Korea.

Authors:  Seo Yeon Baik; Hyunah Kim; So Jung Yang; Tong Min Kim; Seung-Hwan Lee; Jae Hyoung Cho; Hyunyong Lee; Hyeon Woo Yim; Kun-Ho Yoon; Hun-Sung Kim
Journal:  Front Med       Date:  2018-11-27       Impact factor: 4.592

4.  Cholesterol trials and mortality.

Authors:  John B Warren; Simon B Dimmitt; Hans G Stampfer
Journal:  Br J Clin Pharmacol       Date:  2016-05-02       Impact factor: 4.335

5.  Do Statins Induce or Protect from Acute Kidney Injury and Chronic Kidney Disease: An Update Review in 2018.

Authors:  An Verdoodt; Patrick M Honore; Rita Jacobs; Elisabeth De Waele; Viola Van Gorp; Jouke De Regt; Herbert D Spapen
Journal:  J Transl Int Med       Date:  2018-03-28

6.  Simvastatin dose and acute kidney injury without concurrent serious muscle injury: A nationwide nested case-control study.

Authors:  Lianne Parkin; Katrina J Sharples; David J Barson; Mei-Ling Blank
Journal:  PLoS One       Date:  2017-07-28       Impact factor: 3.240

7.  Patterns of statin non-prescription in patients with established coronary artery disease: A report from a contemporary multicenter Japanese PCI registry.

Authors:  Mitsuaki Sawano; Shun Kohsaka; Takayuki Abe; Taku Inohara; Yuichiro Maekawa; Ikuko Ueda; Koichiro Sueyoshi; Masahiro Suzuki; Shigetaka Noma; Yohei Numasawa; Hiroaki Miyata; Keiichi Fukuda; Kim G Smolderen; John A Spertus
Journal:  PLoS One       Date:  2017-08-17       Impact factor: 3.240

8.  Effect of ezetimibe add-on therapy over 52 weeks extension analysis of prospective randomized trial (RESEARCH study) in type 2 diabetes subjects.

Authors:  Kentaro Sakamoto; Mitsunobu Kawamura; Takayuki Watanabe; Keiko Ashidate; Takahide Kohro; Akira Tanaka; Yasumichi Mori; Motoki Tagami; Tsutomu Hirano; Tsutomu Yamazaki; Teruo Shiba
Journal:  Lipids Health Dis       Date:  2017-06-24       Impact factor: 3.876

9.  A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes.

Authors:  Ge Liu; Mingjian Shi; Jonathan D Mosley; Chunhua Weng; Yanfei Zhang; Ming Ta Michael Lee; Gail P Jarvik; Hakon Hakonarson; Bahram Namjou-Khales; Patrick Sleiman; Yuan Luo; Frank Mentch; Joshua C Denny; MacRae F Linton; Wei-Qi Wei; C Michael Stein; QiPing Feng
Journal:  JAMA Netw Open       Date:  2021-06-01

Review 10.  Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract.

Authors:  François Mach; Kausik K Ray; Olov Wiklund; Alberto Corsini; Alberico L Catapano; Eric Bruckert; Guy De Backer; Robert A Hegele; G Kees Hovingh; Terry A Jacobson; Ronald M Krauss; Ulrich Laufs; Lawrence A Leiter; Winfried März; Børge G Nordestgaard; Frederick J Raal; Michael Roden; Raul D Santos; Evan A Stein; Erik S Stroes; Paul D Thompson; Lale Tokgözoglu; Georgirene D Vladutiu; Baris Gencer; Jane K Stock; Henry N Ginsberg; M John Chapman
Journal:  Eur Heart J       Date:  2018-07-14       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.